Daniel Cher, M.D. and W. Carlton Reckling, M.D. are now bringing their talents to California-based SI-Bone, Inc. Dr. Cher, the new vice president of clinical affairs, is an internist with over 15 years of clinical affairs and research experience variety of medical device technology companies. W. Carlton Reckling, M.D., an orthopedic spine surgeon with over 17 years of spine surgery and clinical research experience, was named as vice president of medical affairs.
Dr. Cher, Dr. Reckling Join SI-BONE
2 min read Premium comments
They will work with senior spine surgeons to review SI (sacroiliac) joint data, develop and direct clinical trials, develop and lead physician education programs, and work with the SI-Bone marketing team and key customers to develop a consensus diagnostic process for identification of SI joint conditions.
“Both Daniel and Carlton have had unique and exemplary career experience, which will help build SI-Bone into a formidable medical device technology company, ” said Jeffrey Dunn, CEO and president of SI-Bone, in the March 5, 2012 news release. “I am delighted that they have joined and their addition to the Executive Staff significantly strengthens our team.”
Dr. Cher has experience developing clinical and regulatory strategy, designing and leading clinical trials, and directing clinical research. He has worked at early-stage companies developing new minimally invasive therapies for interventional neuroradiology and for spine surgery. Dr. Cher completed his undergraduate work at Stanford University, followed by Yale Medical School. He then pursued his residency in internal medicine at University of Wisconsin, Madison, and California Pacific Medical Center, in San Francisco. Dr. Cher also trained in general internal medicine and research methods at Stanford University and the Palo Alto VA Hospital.
Dr. Reckling has worked as a spine surgeon in Wyoming and Colorado, where he utilized a number of minimally invasive therapies for different spinal surgical procedures. Educated at Creighton and Northwestern Universities, he pursued his fellowship in spine surgery at Queen’s University Medical Centre in Nottingham, England, and his residency in orthopedic surgery at the University of Minnesota Hospitals and Clinics in Minneapolis, Minnesota.
Dr. Cher told OTW,
My goal is to lead the development and implementation of clinical trials to bring high quality evidence to both the orthopedic community and health plans regarding the safety and effectiveness of iFuse for SI joint fusion in various health conditions.
Dr. Reckling commented to OTW,
My efforts will focus on education of surgeons, healthcare providers, and patients that the SI joint is a significant source of unresolved low back pain (LBP) pain that requires an accurate, comprehensive diagnosis. SI-Bone leads the industry in providing accurate and balanced patient outreach programs, developing Continuing Medical Education (CME) programs that contribute to significant medical clinical progress in low back pain, and addressing requests for information from healthcare providers in a timely manner.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.